Abstract
In order to evaluate dexverapamil as a resistance modifier in acute myeloid leukaemia, we have added dexverapamil (4×300 mg/d orally) to DA chemotherapy (daunorubicin, cytosine arabinoside) in six patients with acute myeloid leukaemia. Two patients (1 first and 1 second relapse) achieved complete remission and two patients (1 refractory disease, 1 third relapse) showed some improvement. One patient in first relapse died due to disease progression and one drug-refractory patient remained refractory. The peak plasma levels of dexverapamil and nordexverapamil ranged from about 600 to 4100 ng/ml and from 450 to 1130 ng/ml, respectively. Major sideeffects were hypotension and sinus bradycardia. These results show the need for further evaluation of dexverapamil as a resistance modifier in acute myeloid leukaemia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D (1992) Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79: 473–476
Harapat SR, Kates RE (1980) High-performance liquid chromatographic analysis of verapamil. J Chromatogr 181: 484–489
Marie PJ, Zittoun R, Sikic BI (1991) Multidrug resistance (mdr1) gene expression in adult leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78: 586–592
Pastan I, Gottesman MM (1987) Multiple-drug resistance in human cancer. N Engl J Med 316: 1388–1393
Pirker R, FitzGerald DJP, Raschack M, Zimmermann F, Willingham MC, Pastan I (1989) Enhancement of the activity of immunotoxins by analogues of verapamil. Cancer Res 49: 4791–4795
Pirker R, Keilhauer G, Raschack M, Lechner C, Ludwig H (1990) Reversal of multidrug resistance in human KB cell lines by structural analogs of verapamil. Int J Cancer 45: 916–919
Pirker R, Wallner J, Geissler K, Linkesch W, Hass OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L, Ludwig H, Lechner K (1991) MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83: 708–712
Pirker R, Wallner J, Gsur A, Götzl M, Zöchbauer S, Scheithauer W, Depisch D (1993) MDR1 gene expression in primary colorectal carcinomas. Br J Cancer 68: 691–694
Sato H, Preisler H, Day R, Raza A, Larson R, Browman G, Goldberg J Vogler R, Grunwald H, Gottlieb A, Bennett J, Gottesman M, Pastan I (1993) MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukemia. Br J Haematol 75: 340–345
Sonneveld P, Nooter K (1990) Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia. Br J Haematol 75: 208–211
Wallner J, Depisch D, Hopfner M, Haider K, Spona J, Ludwig H, Pirker R (1991) MDR1 gene expression and prognostic factors in primary breast carcinomas. Eur J Cancer 27: 1352–1355
Wiernik PH (1989) Acute leukemias. In: De Vita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott, Philadelphia
Zöchbauer S, Gsur A, Brunner R, Kyrle A, Lechner K, Pirker R (1994) P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 8: 974–977
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pirker, R., Zöchbauer, S., Kupper, H. et al. Dexverapamil as resistance modifier in acute myeloid leukaemia. J Cancer Res Clin Oncol 121 (Suppl 3), R21–R24 (1995). https://doi.org/10.1007/BF02351067
Issue Date:
DOI: https://doi.org/10.1007/BF02351067